Core Viewpoint - A commercial dispute over the代理权 of "童颜针" (AestheFill) between *ST苏吴 and爱美客 has escalated, with *ST苏吴 seeking 1.6 billion yuan in arbitration against爱美客's subsidiary, Regen Biotech, for breach of contract [1][5][9]. Group 1: Background of the Dispute - The dispute originated on July 18, when爱美客 sent a termination letter to达透公司, revoking its exclusive distribution rights for AestheFill in mainland China [1][5]. -达透公司 had previously secured exclusive sales rights for AestheFill in China through a tripartite agreement signed in August 2022, valid until August 2032 [2][5]. Group 2: Financial Implications - AestheFill has significantly contributed to *ST苏吴's financial performance, generating 3.26 billion yuan in sales revenue in 2024, accounting for 20.42% of the company's total revenue [10]. - The medical aesthetics sector, driven by AestheFill, reported a staggering revenue increase of 4225.64% year-on-year, reaching 3.03 billion yuan in 2024 [10]. Group 3: Market Dynamics - The "童颜针" market is rapidly expanding, with its size growing from 6 billion yuan in 2023 to over 30 billion yuan in 2024, indicating a strong growth trajectory [12]. - The global market for "童颜针" is projected to reach approximately 1.54 billion USD (about 11.04 billion yuan) by 2025, further highlighting its potential as a lucrative segment [12]. Group 4: Competitive Landscape - The dispute reflects the competitive nature of the medical aesthetics market, with both companies vying for control over a high-margin product that has shown remarkable profitability [14]. - As the number of approved "童颜针" products increases, industry experts predict a potential decline in profit margins due to heightened competition [14].

Core Viewpoint - The acquisition of Regen Biotech by Aimeike has led to a fierce commercial dispute with Jiangsu Wuzhong, the exclusive distributor of AestheFill in mainland China, following Regen's unilateral termination of the distribution agreement [1][2]. Group 1: Background of the Dispute - Jiangsu Wuzhong obtained exclusive distribution rights for AestheFill in mainland China in August 2022, with the product approved for sale in January 2024 [2]. - Aimeike's acquisition of Regen was completed on June 30, 2025, which led to the emergence of conflicts regarding the distribution agreement [2][3]. - On July 21, 2025, Jiangsu Wuzhong received a termination notice from Regen, citing violations of the agreement and concerns over Jiangsu Wuzhong's legal issues affecting AestheFill's brand reputation [2][3]. Group 2: Legal Actions and Claims - Jiangsu Wuzhong has initiated arbitration proceedings against Regen, seeking to confirm the validity of the distribution agreement and claiming damages of 1.6 billion yuan for market development costs and lost profits [3][4]. - The company asserts that it has not transferred its exclusive rights and that the agreement does not allow termination due to administrative penalties against its parent company [3][4]. Group 3: Financial Implications - AestheFill has been a significant revenue driver for Jiangsu Wuzhong, contributing 35.55% of its revenue and 45.77% of its gross profit in Q1 2025 [6]. - The company reported a net profit of 70.48 million yuan in 2024, a 197.97% increase year-on-year, largely attributed to AestheFill sales [6]. - The ongoing dispute threatens Jiangsu Wuzhong's financial stability, as losing the distribution rights could severely impact its revenue and profitability [7]. Group 4: Industry Context - The conflict highlights broader issues within the medical aesthetics industry, where the relationship between brand owners and distributors is often contentious due to the lack of ownership of the brand by distributors [8]. - The uncertainty created by such disputes may lead to a decline in the performance of medical aesthetic products in the market, as distributors may become less motivated to invest in marketing and sales efforts [8].

Market Overview - The Shanghai Composite Index reached a nearly four-year high, closing at 3683.46 points, up 0.48%, surpassing the previous high of 3674.4 points from October 8, 2022 [1] - The total trading volume for the day was 2.15 trillion yuan, marking a significant increase of 269.4 billion yuan compared to the previous trading day [1] - As of August 13, 2025, 3511 stocks, representing 65.9% of the market, have surpassed their opening prices from October 8, 2022 [1] Underperforming Stocks - Despite the overall market rally, 172 stocks closed below their opening prices from September 24, 2022, with the ST sector being particularly affected, accounting for 39 of these stocks [1][2] - The stock *ST Suwu experienced the largest decline, down 87.8%, followed by *ST Zitian at -77.8% [2] Sector Performance - The food and beverage, as well as real estate sectors, are under pressure, with expectations of reaching performance bottoms by mid-2026 [7] - In contrast, the defense and pharmaceutical sectors have seen significant gains, with 60 stocks rising over 200% since October 8, 2022 [8] Notable High Performers - Among the top performers, *ST Yushun saw a remarkable increase of 580.28%, attributed to ongoing major asset restructuring [9] - The stock *ST Suwu led the declines, while other notable gainers include stocks from the basic chemical and medical sectors, with some stocks increasing over 1000% [10][11] Future Outlook - Analysts from Zheshang Securities predict that the market is in a "systematic slow bull" phase, with expectations for the Shanghai Composite Index to exceed previous highs [11] - Pacific Securities indicates a long-term upward trend remains intact, supported by shifting fiscal policies aimed at boosting consumer spending [12]

Core Viewpoint - The dispute over the代理权 of AestheFill (艾塑菲), a high-demand product known as "童颜针," has escalated into a significant arbitration case, with *ST Suwu (600200.SH) seeking damages of up to 1.6 billion yuan against the Korean REGEN company, a subsidiary of Aimeike (爱美客) [1][2][3]. Group 1 - *ST Suwu's subsidiary, Daxiu Medical, has filed for arbitration against Korean REGEN, alleging breach of contract and seeking 1.6 billion yuan in damages [1][3]. - The AestheFill product has generated over 300 million yuan in sales within just eight months, boasting an 82% gross margin, making it a crucial revenue source for *ST Suwu [1][8]. - Aimeike's recent decision to terminate the exclusive distribution agreement with Daxiu Medical has raised concerns about the future of AestheFill's distribution in mainland China [2][3]. Group 2 - Aimeike's revenue growth has been slowing, with a projected revenue of 3.026 billion yuan in 2024, reflecting a mere 5.45% increase compared to over 47% in 2023 [8][9]. - The overall medical aesthetics market in China is expected to grow at a rate of 10% to 15% in the coming years, contrasting with Aimeike's declining performance [9]. - AestheFill's sales accounted for 20.42% of *ST Suwu's total revenue in 2024, significantly contributing to the company's turnaround from losses [9][10].

Core Points - The average stock price of A-shares is 12.74 yuan, with 37 stocks priced below 2 yuan, the lowest being *ST Suwu at 1.04 yuan [1] - Among the low-priced stocks, 13 are ST stocks, accounting for 35.14% of the total [1] - The market performance shows that 6 of the low-priced stocks increased in price, with the highest gainers being Yatai Group, *ST Tianmao, and Pubang Shares, rising by 1.55%, 1.28%, and 1.08% respectively [1] Low-Priced Stock Rankings - The lowest priced stock is *ST Suwu at 1.04 yuan, with a daily decline of 3.70% and a turnover rate of 10.78% [2] - Other notable low-priced stocks include *ST Jinke at 1.41 yuan and Rongsheng Development at 1.43 yuan, both showing no change in price [2] - *ST Tianmao, priced at 1.58 yuan, increased by 1.28% with a turnover rate of 8.07% [2] Market Performance - Among the low-priced stocks, 22 experienced declines, with *ST Gaohong, *ST Suwu, and ST Zhongzhu showing the largest drops of 5.00%, 3.70%, and 2.66% respectively [1][3] - The overall market index, the Shanghai Composite Index, closed at 3683.46 points as of August 13 [1]

Core Viewpoint - The dispute over the exclusive agency rights for the "童颜针" (AestheFill) between *ST Suwu and the medical beauty giant Aimeike has escalated, with *ST Suwu seeking arbitration and claiming significant financial losses due to alleged breaches of contract [2][5][6]. Group 1: Company Actions and Legal Proceedings - *ST Suwu's subsidiary, Datou Medical, has filed for arbitration with the Shenzhen International Arbitration Court regarding a breach of contract by Regen, seeking to confirm its exclusive agency rights for AestheFill and claiming preliminary damages of 1.6 billion yuan [2][6]. - The arbitration request was accepted by the Shenzhen International Arbitration Court on August 7, 2025 [5]. - *ST Suwu has publicly accused Aimeike of "capital bullying" and "serious damage to business ethics" in its defense [2][8]. Group 2: Financial Context and Company Performance - *ST Suwu is facing severe financial difficulties, including risks of forced delisting due to financial fraud allegations, with a reported inflated revenue of 1.77 billion yuan from 2020 to 2023 [3][9]. - Aimeike, which acquired 85% of Regen for $190 million in March 2025, is also experiencing declining financial performance, with revenue and net profit growth rates dropping to single digits in 2024 [3][12]. - Aimeike's market capitalization has decreased from over 180 billion yuan at its peak to approximately 60 billion yuan, reflecting a loss of over 120 billion yuan [4][14]. Group 3: Market Implications and Future Outlook - The ongoing dispute over the AestheFill agency rights is critical for both companies, as AestheFill is seen as a potential growth driver for Aimeike amidst its declining performance [10][11]. - The market has reacted negatively to the news, with *ST Suwu's stock price experiencing consecutive trading halts following the announcement of the termination of its agency rights [8]. - The outcome of the arbitration and the future of the AestheFill product in the Chinese market remain uncertain, with significant implications for both companies and their stakeholders [4][15].

Core Viewpoint - The dispute over the exclusive agency rights for AestheFill between *ST Suwu and REGEN has escalated into legal proceedings, with *ST Suwu's subsidiary, Datou Medical, filing for arbitration to confirm the validity of the exclusive agency agreement and seeking significant compensation for alleged losses [1][2][3]. Group 1: Legal Proceedings and Dispute - Datou Medical has initiated arbitration at the Shenzhen International Arbitration Court, which was formally accepted on August 7, requesting confirmation of the exclusive agency agreement and continuation of supply obligations, along with a compensation claim of up to 1.6 billion yuan for various losses [2][3]. - The partnership between Datou Medical and REGEN began in August 2022, granting Datou Medical exclusive distribution rights for AestheFill in mainland China until August 20232 [2]. - Following the acquisition of 85% of REGEN by Aimei Ke in March 2025, the relationship between the two parties soured, leading to REGEN's termination of the agreement citing breaches by Datou Medical [3]. Group 2: Financial Impact and Product Significance - AestheFill is a key product for *ST Suwu, contributing significantly to its financial performance, with sales revenue reaching 326 million yuan in 2024, accounting for 20.42% of the company's total revenue [4]. - The product's gross profit for 2024 was 269 million yuan, representing 34.8% of the company's total gross profit, indicating its critical role in the company's recovery from previous financial difficulties [4]. - In the first quarter of 2025, AestheFill's sales revenue increased to 113 million yuan, making up 35.55% of the company's revenue, with gross profit rising to 92 million yuan, which accounted for 45.77% of total gross profit [4]. Group 3: Market Dynamics and Industry Implications - The dispute over AestheFill's agency rights highlights the competitive nature of the medical aesthetics industry, where control over distribution channels and pricing can significantly impact revenue and profit margins [6]. - The situation reflects a broader trend in the industry, where companies often rely on blockbuster products to drive performance, indicating a pursuit of short-term profit maximization [6].

爱美客对*ST苏吴方面提起仲裁并不意外，但目前还未正式收 到仲裁机构的口头或书面通知。 作者：刘晓诺 封图：图虫创意 自称"已陷入生死存亡的困境"的*ST苏吴（600200.SH），把AestheFill"童颜针"代理权之争推进 到了法律层面。 8月11日晚，*ST苏吴发布公告，其控股孙公司达透医疗器械（上海）有限公司（下称"达透公 司"）已向深圳国际仲裁院申请仲裁，并已于8月7日获受理立案。仲裁的另一方当事人，便是爱美 客（300896.SZ）间接控股的韩国公司REGEN Biotech,Inc.（下称"REGEN"）。 关于上述仲裁请求，爱美客相关负责人表示："在我们看来，是达透公司有违约行为在先，而且他 们的行为在经济和品牌商誉方面，对我们都有影响。我们也会根据情况采取法律手段，维护我们的 正当权益。" REGEN公司与达透公司的代理权纠纷自2025年7月开始发酵。 "童颜针"AestheFill本是韩国REGEN公司的产品，达透公司具有该产品在中国大陆地区的独家代理 权。2021年底，*ST苏吴花了1.66亿元间接控股了达透公司，并将AestheFill打造为其核心产品。 *ST苏吴称，据不完全统计， ...

Core Viewpoint - The dispute over the exclusive agency rights for AestheFill between Jiangsu Wuzhong and Aimeike has escalated, with Jiangsu Wuzhong initiating arbitration against REGEN for breach of contract after REGEN terminated their exclusive distribution agreement [1][2]. Group 1: Arbitration and Legal Actions - Jiangsu Wuzhong announced on August 11 that it has filed for arbitration with the Shenzhen International Arbitration Court regarding REGEN's breach of contract, seeking to confirm the validity of the exclusive agency agreement for AestheFill until August 28, 2032 [1][2]. - The arbitration request includes demands for REGEN to supply AestheFill products as per the agreement, and if not supported, for REGEN to compensate Jiangsu Wuzhong for losses estimated at RMB 1.6 billion [1][2]. Group 2: Financial Impact and Market Position - As of August 12, Jiangsu Wuzhong's stock price was reported at RMB 1.08 per share, with a market capitalization of RMB 768 million, while Aimeike's stock was at RMB 188.45 per share, with a market capitalization of RMB 57.02 billion [1]. - AestheFill, which was launched in April 2024, contributed over RMB 300 million in revenue to Jiangsu Wuzhong within eight months, highlighting its significance to the company's financial recovery [4][9]. Group 3: Company Strategies and Responses - Following the termination of the agreement, Jiangsu Wuzhong initiated the "W Sunshine Guardian Plan," providing free repair treatments to clients who previously received AestheFill treatments, while also offering training support to partner institutions [11]. - Aimeike has begun selling AestheFill under a new brand name "Zhen Ai Su Fei" in the domestic market, indicating a shift in branding strategy post-dispute [11]. Group 4: Background and Context - The agency rights dispute has roots in Aimeike's acquisition of REGEN in March 2025, which raised concerns about the future of AestheFill's distribution rights [8]. - The legal conflict is compounded by both companies facing performance pressures, with Aimeike's revenue growth slowing significantly and Jiangsu Wuzhong previously reporting six consecutive years of net losses [9].

Core Points - The average stock price of A-shares is 12.63 yuan, with 36 stocks priced below 2 yuan, the lowest being *ST Suwu at 1.08 yuan [1] - Among the low-priced stocks, 12 are ST stocks, accounting for 33.33% of the total [1] - The Shanghai Composite Index closed at 3665.92 points as of August 12 [1] Low-Priced Stocks Summary - The lowest priced stock is *ST Suwu at 1.08 yuan, followed by *ST Jinke at 1.41 yuan and Rongsheng Development at 1.43 yuan [1] - In terms of market performance, 15 of the low-priced stocks increased in price, with ST Zhongzhu rising by 5.03%, *ST Tianmao by 2.63%, and *ST Jinglan by 1.75% [1] - Conversely, 12 stocks decreased in price, with Shandong Steel dropping by 1.29%, Chongqing Steel by 1.28%, and *ST Jinke by 0.70% [1] Detailed Low-Priced Stocks Table - The table includes various low-priced stocks with their latest closing prices, daily price changes, turnover rates, price-to-book ratios, and industries [2] - Notable stocks include ST Zhongzhu at 1.88 yuan with a 5.03% increase, and *ST Xingguang at 1.96 yuan with a 1.03% increase [2]